Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals' board, which met on October 3, 2025, approved a preferential issue of 46,43,000 convertible equity warrants to promoter-group shareholders at Rs. 34 per warrant, aggregating to about Rs. 15.79 crores. Allottees include Anar Jayeshbhai Patel, Dakshesh Rameshchandra Shah, Anar Project Pvt Ltd, Parshva Texchem, and Navkar Surgical Gujarat Ltd. Warrant holders must pay 25% upfront and the remaining 75% at the time of exercising the warrants, which have an 18-month tenure from allotment. The issue is subject to shareholder approval at an Extra-Ordinary General Meeting scheduled for November 1, 2025, with Mrs. Rupal Patel appointed as scrutinizer.
This is a promoter-group capital infusion that signals promoter commitment to the company, but conversion of these warrants into equity shares will dilute the stake of non-promoter shareholders. Near-term stock reaction may be muted since the issue price and premium/discount relative to market is not fully disclosed, but eventual equity dilution is a key consideration.